LLY

906

-0.61%↓

JNJ

239.33

+1.21%↑

ABBV

205.95

-0.37%↓

NVS

149.44

-0.63%↓

MRK

118.95

+1.56%↑

LLY

906

-0.61%↓

JNJ

239.33

+1.21%↑

ABBV

205.95

-0.37%↓

NVS

149.44

-0.63%↓

MRK

118.95

+1.56%↑

LLY

906

-0.61%↓

JNJ

239.33

+1.21%↑

ABBV

205.95

-0.37%↓

NVS

149.44

-0.63%↓

MRK

118.95

+1.56%↑

LLY

906

-0.61%↓

JNJ

239.33

+1.21%↑

ABBV

205.95

-0.37%↓

NVS

149.44

-0.63%↓

MRK

118.95

+1.56%↑

LLY

906

-0.61%↓

JNJ

239.33

+1.21%↑

ABBV

205.95

-0.37%↓

NVS

149.44

-0.63%↓

MRK

118.95

+1.56%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

4.1 0.74

Buy Sell

Overview

Share price change

24h

Current

Min

3.98

Max

4.17

Key metrics
By Trading Economics
Income	466K -27M
Sales	2M 15M
Profit margin	-178.834
Employees	141
EBITDA	-2M -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+264.02% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	2.7M 231M
Previous open	3.36
Previous close	4.1

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

25 mar 2026, 20:20 UTC

Acquisitions, Mergers, Takeovers

Infosys Agrees to Acquire Stratus

25 mar 2026, 23:58 UTC

Earnings

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25 mar 2026, 23:58 UTC

Earnings

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25 mar 2026, 23:57 UTC

Earnings

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25 mar 2026, 23:57 UTC

Earnings

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25 mar 2026, 23:56 UTC

Earnings

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25 mar 2026, 23:56 UTC

Earnings

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25 mar 2026, 23:41 UTC

Market Talk

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25 mar 2026, 23:41 UTC

Earnings

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25 mar 2026, 23:34 UTC

Market Talk

Major News Events

Gold Declines on Possible Technical Correction -- Market Talk

25 mar 2026, 22:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25 mar 2026, 22:08 UTC

Market Talk

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25 mar 2026, 22:07 UTC

Earnings

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25 mar 2026, 22:07 UTC

Earnings

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25 mar 2026, 22:07 UTC

Earnings

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25 mar 2026, 22:07 UTC

Earnings

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25 mar 2026, 22:07 UTC

Earnings

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25 mar 2026, 21:58 UTC

Market Talk

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25 mar 2026, 21:37 UTC

Market Talk

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25 mar 2026, 21:14 UTC

Acquisitions, Mergers, Takeovers

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25 mar 2026, 21:13 UTC

Acquisitions, Mergers, Takeovers

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25 mar 2026, 21:12 UTC

Acquisitions, Mergers, Takeovers

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25 mar 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

25 mar 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

25 mar 2026, 20:33 UTC

Acquisitions, Mergers, Takeovers

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25 mar 2026, 20:31 UTC

Earnings

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25 mar 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25 mar 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25 mar 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25 mar 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

264.02% upside

12 Months Forecast

Average 14.67 USD 264.02%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.